• Je něco špatně v tomto záznamu ?

Association of lncRNA and transcriptome intersections with response to targeted therapy in metastatic renal cell carcinoma

T. Tesarova, K. Koucka, R. Vaclavikova, K. Seborova, M. Hora, O. Hes, K. Pivovarcikova, P. Soucek, O. Fiala

. 2023 ; 26 (3) : 365. [pub] 20230711

Status neindexováno Jazyk angličtina Země Řecko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc23015356

Long non-coding RNAs (lncRNAs) serve an important role in cancer progression and may be used as efficient molecular biomarkers. The present study aimed to identify lncRNAs associated with the response to the receptor tyrosine kinase inhibitor sunitinib and transcriptome profile and clinical features of metastatic renal cell carcinoma (mRCC). The gene expression of 84 cancer-associated lncRNAs in tumor and non-malignant tissue samples of 38 patients with mRCC was evaluated using quantitative PCR. In addition, the coding transcriptome was estimated using RNA sequencing in a subgroup of 20 patients and mRNA-lncRNA intersections were identified. In total, 37 and 13 lncRNAs were down- and upregulated, respectively, in tumor compared with non-malignant adjacent tissue samples. A total of 10 and 4 lncRNAs were up- and downregulated, respectively, in good responders to sunitinib compared with poor responders. High expression of HNF1A-AS1 and IPW lncRNAs was associated with prolonged progression-free survival of patients and a high expression of the TUSC7 lncRNA was associated with poor response and worse survival. Significant associations of dysregulated MEG3 and SNHG16 lncRNAs with expression of protein-coding genes representing various pathways, were identified. Furthermore, a significantly higher expression of CLIP4 gene was observed in good responders. The present study revealed promising candidates for predictive and prognostic biomarkers with further therapeutic potential.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23015356
003      
CZ-PrNML
005      
20231020093534.0
007      
ta
008      
231010s2023 gr f 000 0|eng||
009      
AR
024    7_
$a 10.3892/ol.2023.13951 $2 doi
035    __
$a (PubMed)37559591
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gr
100    1_
$a Tesarova, Tereza $u Laboratory of Pharmacogenomics, Biomedical Center, Faculty of Medicine in Pilsen, Charles University, 323 00 Pilsen, Czech Republic $u Toxicogenomics Unit, National Institute of Public Health, 100 00 Prague 10, Czech Republic
245    10
$a Association of lncRNA and transcriptome intersections with response to targeted therapy in metastatic renal cell carcinoma / $c T. Tesarova, K. Koucka, R. Vaclavikova, K. Seborova, M. Hora, O. Hes, K. Pivovarcikova, P. Soucek, O. Fiala
520    9_
$a Long non-coding RNAs (lncRNAs) serve an important role in cancer progression and may be used as efficient molecular biomarkers. The present study aimed to identify lncRNAs associated with the response to the receptor tyrosine kinase inhibitor sunitinib and transcriptome profile and clinical features of metastatic renal cell carcinoma (mRCC). The gene expression of 84 cancer-associated lncRNAs in tumor and non-malignant tissue samples of 38 patients with mRCC was evaluated using quantitative PCR. In addition, the coding transcriptome was estimated using RNA sequencing in a subgroup of 20 patients and mRNA-lncRNA intersections were identified. In total, 37 and 13 lncRNAs were down- and upregulated, respectively, in tumor compared with non-malignant adjacent tissue samples. A total of 10 and 4 lncRNAs were up- and downregulated, respectively, in good responders to sunitinib compared with poor responders. High expression of HNF1A-AS1 and IPW lncRNAs was associated with prolonged progression-free survival of patients and a high expression of the TUSC7 lncRNA was associated with poor response and worse survival. Significant associations of dysregulated MEG3 and SNHG16 lncRNAs with expression of protein-coding genes representing various pathways, were identified. Furthermore, a significantly higher expression of CLIP4 gene was observed in good responders. The present study revealed promising candidates for predictive and prognostic biomarkers with further therapeutic potential.
590    __
$a NEINDEXOVÁNO
655    _2
$a časopisecké články $7 D016428
700    1_
$a Koucka, Kamila $u Laboratory of Pharmacogenomics, Biomedical Center, Faculty of Medicine in Pilsen, Charles University, 323 00 Pilsen, Czech Republic
700    1_
$a Vaclavikova, Radka $u Laboratory of Pharmacogenomics, Biomedical Center, Faculty of Medicine in Pilsen, Charles University, 323 00 Pilsen, Czech Republic $u Toxicogenomics Unit, National Institute of Public Health, 100 00 Prague 10, Czech Republic
700    1_
$a Seborova, Karolina $u Laboratory of Pharmacogenomics, Biomedical Center, Faculty of Medicine in Pilsen, Charles University, 323 00 Pilsen, Czech Republic
700    1_
$a Hora, Milan $u Department of Urology, Faculty of Medicine in Pilsen and University Hospital, Charles University, 301 00 Pilsen, Czech Republic
700    1_
$a Hes, Ondrej $u Department of Pathology, Faculty of Medicine in Pilsen and University Hospital, Charles University, 301 00 Pilsen, Czech Republic
700    1_
$a Pivovarcikova, Kristyna $u Department of Pathology, Faculty of Medicine in Pilsen and University Hospital, Charles University, 301 00 Pilsen, Czech Republic
700    1_
$a Soucek, Pavel $u Laboratory of Pharmacogenomics, Biomedical Center, Faculty of Medicine in Pilsen, Charles University, 323 00 Pilsen, Czech Republic $u Toxicogenomics Unit, National Institute of Public Health, 100 00 Prague 10, Czech Republic
700    1_
$a Fiala, Ondrej $u Department of Oncology and Radiotherapeutics, Faculty of Medicine in Pilsen and University Hospital, Charles University, 323 00 Pilsen, Czech Republic $u Laboratory of Cancer Treatment and Tissue Regeneration, Biomedical Center, Faculty of Medicine in Pilsen, Charles University, 323 00 Pilsen, Czech Republic
773    0_
$w MED00193499 $t Oncology letters $x 1792-1082 $g Roč. 26, č. 3 (2023), s. 365
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37559591 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20231010 $b ABA008
991    __
$a 20231020093527 $b ABA008
999    __
$a ok $b bmc $g 1997109 $s 1201718
BAS    __
$a 3
BAS    __
$a PreBMC-PubMed-not-MEDLINE
BMC    __
$a 2023 $b 26 $c 3 $d 365 $e 20230711 $i 1792-1082 $m Oncology letters $n Oncol Lett $x MED00193499
LZP    __
$a Pubmed-20231010

Najít záznam

Citační ukazatele

Možnosti archivace